Rapt Therapeutics Inc logo

RAPT - Rapt Therapeutics Inc Share Price

$29.42 -4.3  -12.8%

Last Trade - 7:45pm

Sector
Healthcare
Size
Mid Cap
Market Cap £648.1m
Enterprise Value £543.7m
Revenue £1.74m
Position in Universe 2496th / 6389
Bullish
Bearish
Unlock RAPT Revenue
Momentum
Relative Strength (%)
1m +38.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -34.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Rapt Therapeutics Inc revenues increased from $0K to $2.2M. Net loss increased 29% to $25.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 26% to $19.8M (expense), Stock-based Compensation in R&D increase from $399K to $1.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RAPT Revenue Unlock RAPT Revenue

Net Income

RAPT Net Income Unlock RAPT Revenue

Normalised EPS

RAPT Normalised EPS Unlock RAPT Revenue

PE Ratio Range

RAPT PE Ratio Range Unlock RAPT Revenue

Dividend Yield Range

RAPT Dividend Yield Range Unlock RAPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RAPT EPS Forecasts Unlock RAPT Revenue
Profile Summary

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated March 4, 2015
Public Since October 31, 2019
No. of Shareholders: n/a
No. of Employees: 71
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 24,468,910
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RAPT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RAPT
Upcoming Events for RAPT
Frequently Asked Questions for Rapt Therapeutics Inc
What is the Rapt Therapeutics Inc share price?

As of 7:45pm, shares in Rapt Therapeutics Inc are trading at $29.42, giving the company a market capitalisation of £648.1m. This share price information is delayed by 15 minutes.

How has the Rapt Therapeutics Inc share price performed this year?

Shares in Rapt Therapeutics Inc are currently trading at $29.42 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rapt Therapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Rapt Therapeutics Inc?

There are no analysts currently covering Rapt Therapeutics Inc.

When will Rapt Therapeutics Inc next release its financial results?

Rapt Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Rapt Therapeutics Inc dividend yield?

Rapt Therapeutics Inc does not currently pay a dividend.

Does Rapt Therapeutics Inc pay a dividend?

Rapt Therapeutics Inc does not currently pay a dividend.

When does Rapt Therapeutics Inc next pay dividends?

Rapt Therapeutics Inc does not currently pay a dividend.

How do I buy Rapt Therapeutics Inc shares?

To buy shares in Rapt Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rapt Therapeutics Inc?

Shares in Rapt Therapeutics Inc are currently trading at $29.42, giving the company a market capitalisation of £648.1m.

Where are Rapt Therapeutics Inc shares listed? Where are Rapt Therapeutics Inc shares listed?

Here are the trading details for Rapt Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: RAPT
What kind of share is Rapt Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Rapt Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rapt Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Rapt Therapeutics Inc.

How can I tell whether the Rapt Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapt Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 36.18%. At the current price of $29.42, shares in Rapt Therapeutics Inc are trading at 34.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rapt Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Rapt Therapeutics Inc.

Who are the key directors of Rapt Therapeutics Inc?

Rapt Therapeutics Inc's management team is headed by:

William Ho - OTH
Brian Wong - PRE
Paul Kassner - SVP
Rodney Young - CFO
Mary Gray - IND
Lisa Moore - VPR
Dirk Brockstedt - CSO
Michael Giordano - IND
Peter Svennilson - DRC
Linda Kozick - IND
William Rieflin - IND
Phyllis Gray - VPR
Who are the major shareholders of Rapt Therapeutics Inc?

Here are the top five shareholders of Rapt Therapeutics Inc based on the size of their shareholding:

The Column Group LP Venture Capital
Percentage owned: 25.5% (6.24m shares)
Kleiner, Perkins, Caufield & Byers Venture Capital
Percentage owned: 14.5% (3.55m shares)
The Regents of the University of California Endowment Fund
Percentage owned: 6.43% (1.57m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 5.85% (1.43m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 4.83% (1.18m shares)
Similar to RAPT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.